Imagen de Portada
Código QR

HYBRID CLOUD ARCHITECTURE: IN PHARMACEUTICAL DEVELOPMENT AND MANUFACTURING.

The article focuses on how hybrid cloud architecture enables pharmaceutical and biotechnology organizations to accelerate drug development while maintaining regulatory compliance and protecting intellectual property. It explains that hybrid cloud combines the scalability of public clouds with the se...

Descripción completa

Publicado en:Pharmaceutical Technology Vol. 50; no. 3; pp. 10 - 15
Autor principal: ANBIL, PARTHA S.
Formato: pictorial questions and answers tables/charts Journal Article
Publicado: MJH Life Sciences May/Jun2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=194145717&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 194145717
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15432521
        4FK
      jtl: Pharmaceutical Technology
      issn: 15432521
      maglogo: N
    pubinfo:
      dt: May/Jun2026
      vid: 50
      iid: 3
      pid: 54670
      pub: MJH Life Sciences
      place: Cranbury, New Jersey
    artinfo:
      ui:
        194145717
        194145717
        194145717
        194145717
      ppf: 10
      ppct: 5
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: HYBRID CLOUD ARCHITECTURE: IN PHARMACEUTICAL DEVELOPMENT AND MANUFACTURING.
      aug:
        au: ANBIL, PARTHA S.
        affil: Senior vice president of life sciences at Coforge Ltd
      sug:
        subj:
          Cloud Computing
          Technology, Pharmaceutical
          Artificial Intelligence
          Drug Compounding Economics
          Data Security
          Machine Learning
          Clinical Trials
          Electronic Health Records
          Information Retrieval
          Quality Assurance
          Healthcare Supply Chain
          Privacy and Confidentiality
          Computing Methodologies
          Data Management
          Pharmaceutical Companies
          Drug Discovery
          Drug Development
          Manufacturing Industry
      ab: The article focuses on how hybrid cloud architecture enables pharmaceutical and biotechnology organizations to accelerate drug development while maintaining regulatory compliance and protecting intellectual property. It explains that hybrid cloud combines the scalability of public clouds with the security and control of private infrastructure, addressing stringent regulations such as FDA 21 CFR Part 11 and emerging AI governance frameworks from the FDA and European Medicines Agency. The article details hybrid deployment patterns—such as data residency tiering, federated learning, and cloudbursting—that optimize workload segmentation based on data sensitivity and computational needs across drug discovery, clinical trials, manufacturing, and supply chain management. It also highlights industry examples, including the collaboration between Eli Lilly and NVIDIA, demonstrating how hybrid cloud supports Pharma 4.0 initiatives and global regulatory adherence. The article concludes that successful hybrid cloud adoption requires organizational capability development and a graduated implementation approach to balance innovation with compliance and data integrity.
      pubtype: Trade Publication
      doctype:
        pictorial
        questions and answers
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N